A 38-year-old man with refractory follicular lymphoma underwent allogeneic BMT from an HLA-identical sibling donor. He had generalized lymphadenopathy, hepatosplenomegaly and lymphoma infiltration of the marrow, all of which disappeared within 3 months following transplantation. Six months post-transplant, progressive hepatomegaly developed in the absence of splenomegaly and lymphadenopathy, and he died from hepatic failure. Autopsy disclosed diffuse large B cell lymphoma of the liver, into which the follicular lymphoma had transformed. Future issues to be investigated should include the optimal timing of allogeneic BMT for lowgrade lymphomas. Bone Marrow Transplantation (2000) 26, 581-583.
The long-term history and indolent nature of low-grade non-Hodgkin's lymphoma do not always support an early choice of aggressive treatment. However, regardless of initial sensitivity to chemotherapy and radiotherapy, relapse is inevitable and, therefore, treatment choice especially for younger patients is a serious decision. Recently, high-dose therapy followed by transplantation from an HLA-identical sibling has been reported to be successful in prolonging survival in patients with chemotherapy-resistant low-grade lymphomas. [1] [2] [3] Although a major problem has been the high transplant-related mortality, previous studies have shown that relapses of the lymphoma are much lower in these recipients. We describe the first case of refractory follicular lymphoma in which histologic transformation occurred after allogeneic bone marrow transplantation (allo-BMT). 
Case report
A 38-year-old Japanese man with 7-year history of refractory follicular lymphoma underwent allo-BMT from an HLA-identical sibling donor in January 1999. He had been unsuccessfully treated with chemotherapeutic agents including doxorubicin, bleomycin, cyclophosphamide, vincristine, prednisolone, etoposide and cisplatin. On physical examination, superficial lymphadenopathy was found in various regions including the neck, axilla and groin. The spleen was enlarged 10 cm below the costal margin and the liver 8 cm. Hemoglobin concentration was 5.8 g/dl, white blood cell count 2.6 × 10 9 /l with 23% lymphoma cells, and platelet count 125 × 10 9 /l. Serum lactate dehydrogenase (LDH) level was 1012 IU/l (normal value: Ͻ480 IU/l), which appeared to have almost continuously increased from a level at initial diagnosis of 372 IU/l. A bone marrow aspirate revealed infiltration by lymphoma cells. Computed tomographic (CT) scan of the abdomen showed massive hepatosplenomegaly and mesenteric lymphadenopathy. Biopsy of a cervical lymph node showed the histologic features of follicular lymphoma grade II under the Revised European-American Lymphoma classification, which remained unchanged from the initial diagnosis ( Figure 1 ).
High-dose cyclophosphamide (120 mg/kg) followed by fractionated total-body irradiation (12 Gy in six fractions) were used as conditioning and standard-dose cyclosporin with 'short' methotrexate for graft-versus-host disease (GVHD) prophylaxis. On day 22, grade II acute GVHD involving the skin and gastrointestinal tract was documented but resolved with oral prednisolone (1 mg/kg/day). Hepatosplenomegaly and enlarged lymph nodes disappeared within 3 months. On day 151, he underwent urgent jejunal enterectomy because of occlusive ileus probably associated with gastrointestinal GVHD. At the time of the operation, no tumor masses or enlargement of lymph nodes in the mesenterium could be found in the abdomen. The resected specimen of jejunum also showed no histological evidence of lymphoma.
Six months post transplant, progressive hepatomegaly developed in the absence of splenomegaly and lymphadenopathy. An abdominal CT scan revealed a 9 × 8 × 8 cm tumor in the right lobe of the liver and ultrasound-guided fine needle biopsy of the tumor revealed involvement by Autopsy disclosed diffuse large B cell lymphoma exclusively involving the right hepatic lobe, and several lymph nodes in the hilar region of the liver (Figure 1) . In situ hybridization analysis using an oligonucleotide probe complementary to Epstein-Barr virus (EBV)-encoded RNA-1 (Dako, Kyoto, Japan) revealed negative signals in these cells. Southern blotting of DNA from the lymphoma cells using a 2.8-kb EcoRI/HindIII genomic fragment containing a 3Ј part of the major breakpoint cluster region (Oncor, Gaithersburg, MD, USA) showed rearranged Bcl2 fragments. As shown in Figure 2 , the pre-and post-transplant lymphomas were of identical size (207 bp) of polymerase chain reaction (PCR)-amplified fragments by immunoglobulin heavy chain gene consensus primers. 4 DNA sequencing of the two rearranged fragments revealed 95.7% homology at the nucleotide level and 95.6% homology predicted at the amino acid level.
Discussion
It is unlikely that the diffuse large B cell lymphoma was so-called post-transplant lymphoproliferative disease (PTLPD), because the EBV-negative tumor cell proliferation and poor responses to reduction of immunosuppres- sion and the DLI are uncommon in PTLPD. 5 An identical PCR-amplified rearranged fragment of immunoglobulin heavy chain gene between pretransplant and post-transplant lymphomas and Bcl2 gene rearrangement in the latter strongly imply that the two clones were, in fact, part of the same clone in which transformation had occurred.
We could not clarify whether the transformation process was, indeed, initiated after allo-BMT, because a primitive genetic event which would precede a sequence of genetic events and eventual histologic transformation has not been identified. From a clinical viewpoint, however, the temporary disappearance of the hepatomegaly after BMT and the fact that the hepatic tumor was undetectable during the pretransplant and early post-transplant periods may suggest that at least the proliferation of the transformed clone occurred after allo-BMT. Since the transformed diffuse large B cell lymphoma rapidly grew, escaping the graftversus-lymphoma (GVL) surveillance, it is likely that a follicular lymphoma clone which remained after the BMT, and which might or might not already have been undergoing transformation, acquired crucial genetic mutation(s) for the transformed lymphoma phenotype and overcame the GVL effect. It is also possible that the immunosuppression secondary to allo-BMT favored transformation of the original clone. 6 Allo-BMT offers a tumor-free bone marrow, a GVL effect and a low risk of secondary leukemias, and some authors have suggested an advantage of allogeneic over autologous stem cell transplantation in younger patients with advanced-stage low-grade lymphoma. [1] [2] [3] However, our clinical experience implies that patients with low-grade lymphomas may have the best outcome when they are treated early in their course when they have little bulky disease which is non-transformed and chemosensitive. We consider that future issues to be investigated should include optimal timing of allo-BMT for low-grade lymphomas. In this context, a sensitive prognostic model would help identify patients with a poor prognosis who would benefit from allo-BMT. 7 Novel approaches such as the use of a nonmyeloablative preparative regimen may decrease transplantrelated mortality, 8 which has dissuaded physicians from an early choice of allo-BMT for treatment of low-grade lymphomas. 9 
